Interatrial shunt devices market seen reaching $4.71 billion by 2030

The Business Research Company says the interatrial shunt devices market will rise from $2.9 billion in 2025 to $3.2 billion in 2026, then climb to $4.71 billion by 2030. The report points to rising heart failure cases, broader use of minimally invasive care and faster growth in Asia-Pacific as key forces behind demand.

Why it matters: - Interatrial shunt devices are aimed at patients with heart failure, a condition that is growing worldwide and needs more treatment options. - The market outlook suggests sustained demand for minimally invasive cardiac devices as healthcare systems look for ways to reduce symptoms and manage pressure in the heart.

What happened: - The Business Research Company released an interatrial shunt devices market intelligence report on Aug. 12, 2026. - The report forecasts the market will grow from $2.9 billion in 2025 to $3.2 billion in 2026. - The report projects the market will reach $4.71 billion by 2030. - The company estimates a 10.3% CAGR from 2025 to 2026 and a 10.1% CAGR through 2030.

The details: - Interatrial shunt devices are implantable medical tools that create a controlled opening between the left and right atria. - The devices allow blood to flow from the left atrium to the right atrium to reduce pressure and ease heart failure symptoms. - Lower left atrial pressure can help reduce pulmonary congestion and improve cardiac function. - The report ties near-term market growth to rising heart failure prevalence, more awareness of interatrial shunt therapies, advances in cardiac imaging, more cardiac catheterization procedures and supportive reimbursement policies. - The report links longer-term growth to technological innovation, wider use of transcatheter delivery methods, an aging population with cardiovascular disease, greater use of minimally invasive procedures and more personalized heart failure management. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to grow the fastest during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The report offers a free sample here. - The full report is available here.

Between the lines: - Heart failure prevalence is the clearest demand signal in the report, and that makes the market tightly linked to broader cardiovascular disease trends. - North America’s lead suggests established reimbursement, infrastructure and adoption remain key advantages. - Faster expected growth in Asia-Pacific points to expanding clinical demand and healthcare modernization outside the U.S. and Europe.

What's next: - The market is expected to keep expanding through 2030 if adoption of transcatheter and minimally invasive therapies continues to rise. - The report’s forecast implies continued interest from device makers, investors and providers focused on heart failure care. - The company invites readers to request a sample or view the full report for more detail.